Clinical and Translational Research
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2610-2630
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2610
Epidemiology and prognostic nomogram for locally advanced gastric signet ring cell carcinoma: A population-based study
Ze-Hao Yu, Lei-Ming Zhang, Zhi-Qi Dai, Meng-Na Zhang, Si-Ming Zheng
Ze-Hao Yu, Zhi-Qi Dai, Meng-Na Zhang, Si-Ming Zheng, Health Science Center, The First Affiliated Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China
Ze-Hao Yu, Lei-Ming Zhang, Zhi-Qi Dai, Health Science Center, Ningbo University, Ningbo 315211, Zhejiang Province, China
Meng-Na Zhang, College of Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou 310058, Zhejiang Province, China
Co-first authors: Ze-Hao Yu and Lei-Ming Zhang.
Author contributions: Yu ZH and Zhang LM designed and performed the research and wrote the paper; Zheng SM supervised the report; Dai ZQ and Zhang MN contributed to the analysis. Yu ZH and Zhang LM contributed equally to this work as co-first authors. The reasons for designating Yu ZH and Zhang LM as co-first authors are twofold. First, the research was conducted as a collaborative effort, and the designation of co-first authors accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately improving the quality and reliability of the paper. Second, Yu ZH and Zhang LM made equal contributions throughout the research process. Choosing these researchers as co-first authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Yu ZH and Zhang LM as co-first authors is fitting for our manuscript, as it accurately reflects our team's collaborative spirit and equal contributions.
Supported by the TCM Science and Technology Plan Project of Zhejiang Province, No. 2022ZB323; the Medical and Health Science and Technology Plan Project of Zhejiang Province, No. 2022KY1114; and the Basic Research Program of Ningbo, No. 2023Z210.
Conflict-of-interest statement: Dr. Zheng has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Si-Ming Zheng, MD, Doctor, Health Science Center, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Haishu District, Ningbo 315000, Zhejiang Province, China. 29010921@qq.com
Received: January 5, 2024
Revised: April 6, 2024
Accepted: April 12, 2024
Published online: June 15, 2024
Processing time: 161 Days and 23.4 Hours
Core Tip

Core Tip: In the United States, there has been a downward trend in the incidence and mortality rates of gastric signet ring cell carcinoma (GSRC) over time, and these optimistic trends may be credited to the implementation of cancer screenings and the advancements in novel treatment approaches in the past few decades. Additionally, the model we established can help clinicians in early identification of the prognosis of locally advanced GSRC patients, resulting in enhanced clinical outcomes by modifying management strategies and patient healthcare.